Precision BioSciences Inc. Beats Earnings and Revenue Forecasts - DTIL Surges

Precision BioSciences Inc. (NASDAQ:DTIL) Surpasses Earnings and Revenue Estimates

Precision BioSciences Inc. (NASDAQ:DTIL) reported quarterly adjusted earnings of $0.36 per share, significantly beating the Zacks Consensus Estimate of a -$0.21 loss per share. This represents an earnings surprise of +271.43% and marks a substantial improvement from the adjusted loss of $3.2 per share in the same quarter the previous year.

The company's revenue for the quarter ended December 31, 2025, was $34.2 million, exceeding the Zacks Consensus Estimate by 178.08%. This reflects a dramatic increase from $0.6 million in the prior-year quarter, driven largely by collaboration-related payments (including completions from programs like Novartis). Despite the strong beat, the company has exceeded consensus revenue estimates only once in the last four quarters.

Precision BioSciences, a clinical-stage gene editing company, operates in the Zacks Medical - Biomedical and Genetics industry. The company announced its Q4 and fiscal year 2025 financial results on March 12, 2026.

On March 13, 2026, Maury Raycroft from Jefferies set a price target of $19 for DTIL (lowered from a prior $21), maintaining a positive outlook with the note that the near-term setup remains attractive. At the time, the stock was trading around $5.67, implying a significant potential upside of approximately 235% (from $5.67 to $19).

The company's market capitalization is approximately $130 million, with trading volume on March 13, 2026, at 277,693 shares. Over the past year, DTIL's stock has ranged from a low of $3.53 to a high of $8.82. On March 13, 2026, the stock traded between a low of approximately $5.40 and a high of $6.05, closing at $5.67.

Precision BioSciences has made notable clinical progress, particularly with its PBGENE-HBV program for chronic hepatitis B. The company presented late-breaking Phase 1 data from the ELIMINATE-B trial at AASLD The Liver Meeting® 2025 (held in November 2025), demonstrating safety, tolerability across repeat administrations, and cumulative, dose-dependent antiviral activity (including HBsAg declines). Paired biopsy findings provided the first molecular evidence consistent with gene editing of viral DNA (cccDNA and integrated HBV DNA) in patients. With 13 patients now dosed across the first five cohorts, additional data updates are expected at medical conferences throughout 2026.

CEO Michael Amoroso highlighted these advancements as positioning the company for continued success in 2026 and beyond, supported by an extended cash runway through 2028 following the strong quarterly results.